Neomed Management
VC Fund
Oslo, Norway
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date. NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries. NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America. From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies. NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 13%
- Fund size:
- $51M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Neomed Management invests in
Stages Neomed Management invests in
Countries Neomed Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $8.3M–$37M
- Series B
- $21M–$42M
- Series C
- $9.2M–$44M
Investment Focus
Industry
- Health Care 18 (39%)
- Biotechnology 18 (39%)
- Medical 9 (20%)
- Medical Device 8 (17%)
- Pharmaceutical 5 (11%)
Stage
- Series B 11 (24%)
- Series C 8 (17%)
- Series A 5 (11%)
- Funding Round 4 (9%)
- Series D 3 (7%)
Country
- Switzerland 8 (17%)
- United States 6 (13%)
- Sweden 2 (4%)
- United Kingdom 2 (4%)
- Italy 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erik Amble
Founder, Chairman & Managing Partner
|
Founder, Chairman & Managing Partner | Total investments: 11 | Find email | |
Thomas Goebel
Principal
|
Principal | Total investments: 2 | Find email | |
Vincent Ossipow
Partner
|
Partner | Total investments: 5 | Find email | |
Claudio Nessi
Partner
|
Partner | Total investments: 18 | Find email | |
Line B. Westlund
Office Manager
|
Office Manager | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. | $37M / Series B / Mar 01, 2021 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M / Venture - Series Unknown / Feb 05, 2020 | ||
| Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $85M / Jan 06, 2020 | ||
| Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $9.8M / Series D / Oct 16, 2018 | ||
| Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $50M / Private Equity / Sep 18, 2017 | ||
| Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions.The company was founded in 2012 andis based in Lebanon, New Hampshire. | $12M / Series E / Jun 21, 2017 | ||
| Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $14.5M / Series C / May 02, 2017 | ||
| Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $35M / Series E / Dec 13, 2016 | ||
| 4Tech is a one-stop shop for plastic moldings and packaging solutions from design to manufacture. It was founded in 2011 and is based in Waltham, Massachusetts. | $29M / Series B / Mar 09, 2016 | ||
| Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $38.5M / Series B / Dec 22, 2015 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Neomed Management invest in?
Neomed Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 46 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Neomed Management invest in?
Neomed Management typically joins rounds of $8.3M–$37M at Series A, $21M–$42M at Series B and $9.2M–$44M at Series C. These are whole funding-round sizes, not Neomed Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Neomed Management took part in.
How do I contact Neomed Management?
Public channels for Neomed Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Neomed Management?
The team at Neomed Management includes Erik Amble (Founder, Chairman & Managing Partner), Thomas Goebel (Principal) and Vincent Ossipow (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
